Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Macrogenics Inc (MGNX)  
$14.56 0.19 (1.32%) as of 4:30 Fri 4/26


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 62,030,000
Market Cap: 903.16(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $4.48 - $21.47
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   MacroGenics is a biopharmaceutical company. Co.'s main pipeline program is MGC018, an antibody-drug conjugate that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Co. is also developing enoblituzumab, an Fc-optimized monoclonal antibody that targets B7-H3 and molecules that target programmed cell death protein 1, a protein that is important in the regulation of the immune system's response to cancer. In addition, Co. is developing MGD024, a bispecific DART molecule that engages CD3 on immune effector cells to kill CD123-expressing cancer cells in certain hematological malignancies, including acute myeloid leukemia.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 350,000 2,394,399
Total Buy Value $0 $0 $1,722,425 $11,462,434
Total People Bought 0 0 1 2
Total Buy Transactions 0 0 2 11
Total Shares Sold 261,204 293,400 293,400 298,772
Total Sell Value $4,645,136 $4,995,238 $4,995,238 $5,027,631
Total People Sold 5 5 5 5
Total Sell Transactions 9 11 11 12
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 286
  Page 2 of 12  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Koenig Scott President and CEO   •       •      –    2024-02-15 4 OE $0.00 $0 D/D 42,341 1,091,977     -
   Spitznagel Thomas Sr VP, Technical Ops   •       –      –    2024-02-15 4 D $17.40 $87,348 D/D (5,020) 8,316     -
   Spitznagel Thomas Sr VP, Technical Ops   •       –      –    2024-02-15 4 OE $0.00 $0 D/D 13,336 13,336     -
   Bonvini Ezio Sr VP, Research & CSO   •       –      –    2024-02-07 4 AS $18.00 $60,012 D/D (3,334) 71,334 -16%     
   Peters Jeffrey Stuart Senior VP and General Counsel   •       –      –    2024-02-05 4 AS $16.50 $1,258,142 D/D (76,251) 0 -13%     
   Peters Jeffrey Stuart Senior VP and General Counsel   •       –      –    2024-02-05 4 OE $10.15 $847,355 D/D 76,251 76,251     -
   Bonvini Ezio Sr VP, Research & CSO   •       –      –    2024-02-01 4 AS $15.00 $199,740 D/D (13,316) 74,668 -5%     
   Bonvini Ezio Sr VP, Research & CSO   •       –      –    2024-01-19 4 AS $12.00 $159,792 D/D (13,316) 87,984 21%     
   Bonvini Ezio Sr VP, Research & CSO   •       –      –    2023-12-20 4 AS $10.08 $190,310 D/D (18,880) 101,300 48%     
   Bb Biotech Ag 10% Owner   –       –       •   2023-10-02 4 B $4.46 $669,585 D/D 150,000 9,929,963 2.45 287%     
   Bb Biotech Ag 10% Owner   –       –       •   2023-09-07 4 B $5.26 $1,052,840 D/D 200,000 9,779,963 2.45 100%     
   Peters Jeffrey Stuart Senior VP and General Counsel   •       –      –    2023-03-10 4 AS $6.03 $32,393 D/D (5,372) 0 -9%     
   Peters Jeffrey Stuart Senior VP and General Counsel   •       –      –    2023-02-22 4 D $6.55 $22,126 D/D (3,378) 5,372     -
   Peters Jeffrey Stuart Senior VP and General Counsel   •       –      –    2023-02-22 4 OE $0.00 $0 D/D 8,750 8,750     -
   Bonvini Ezio Sr VP, Research & CSO   •       –      –    2023-02-22 4 D $6.55 $23,704 D/D (3,619) 120,180     -
   Bonvini Ezio Sr VP, Research & CSO   •       –      –    2023-02-22 4 OE $0.00 $0 D/D 9,375 123,799     -
   Bb Biotech Ag 10% Owner   –       –       •   2023-02-14 4 B $5.07 $2,532,600 D/D 500,000 9,579,963 2.45 3%     
   Bb Biotech Ag 10% Owner   –       –       •   2023-01-19 4 B $5.30 $794,925 D/D 150,000 9,079,963 2.45 -11%     
   Bb Biotech Ag 10% Owner   –       –       •   2022-12-27 4 B $5.61 $1,121,800 D/D 200,000 8,929,963 2.45 29%     
   Bb Biotech Ag 10% Owner   –       –       •   2022-12-23 4 B $5.88 $1,176,800 D/D 200,000 8,729,963 2.45 20%     
   Risser Eric Blasius Chief Operating Officer   •       –      –    2022-10-28 4 OE $1.51 $12,835 D/D 8,500 53,468     -
   Bb Biotech Ag 10% Owner   –       –       •   2022-10-24 4 B $4.36 $1,090,500 D/D 250,000 8,229,963 2.45 25%     
   Bb Biotech Ag 10% Owner   –       –       •   2022-10-21 4 B $4.63 $1,157,100 D/D 250,000 7,979,963 2.45 22%     
   Bb Biotech Ag 10% Owner   –       –       •   2022-10-20 4 B $4.00 $1,143,565 D/D 285,977 7,729,963 2.45 42%     
   Bb Biotech Ag 10% Owner   –       –       •   2022-10-19 4 B $3.70 $623,919 D/D 168,422 7,443,986 2.45 59%     
  286 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 2 of 12
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us